Pharma News

Formycon launches biosimilar ranibizumab Ravegza in Saudi, Gedeon Richter invests

Home/Pharma News | Posted 07/05/2024

In March 2024, Formycon and MS Pharma announced that their FYB201/ranibizumab Ravegza, a biosimilar to Lucentis, has received marketing authorization from the Saudi Food and Drug Authority.

mAbxience and Biosidus sign an agreement to manufacture Agalsidase Beta

Home/Pharma News | Posted 09/04/2024

mAbxience announced in February 2024 a pivotal agreement with Biosidus to manufacture Agalsidase Beta. This joint effort is expected to have a significant impact on the lives of patients affected by Fabry disease.

Biosimilars lawsuits and settlement updates for Regeneron and Alvotech

Home/Pharma News | Posted 22/03/2024

In January 2024, Regeneron filed a lawsuit against Amgen in the federal court in Los Angeles, alleging Amgen's proposed biosimilar of Regeneron's Eylea (aflibercept) violates patent rights. Additionally, in February 2024, Iceland-based Alvotech announced the anticipated global market entry dates for AVT04, a ustekinumab biosimilar to Stelara, following its settlement with Johnson & Johnson.

The journey of Pectuna pertuzumab follow-on biological in Iran

Home/Pharma News | Posted 29/02/2024

Pertuzumab is a monoclonal antibody (mAb) that inhibits the dimerization of human epidermal growth factor receptor 2 (HER2) with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation. It is a pivotal therapeutic in oncology, targeting the overexpressed HER2 protein, particularly in breast cancer [1].

Sandoz US acquisition of ranibizumab biosimilar from Coherus

Home/Pharma News | Posted 09/02/2024

On 22 January 2024, it was announced that in the US, Sandoz will acquire ranibizumab biosimilar Cimerli (ranibizumab) from Coherus BioSciences.

Fiocruz and Pfizer sign agreement for generic of Xeljanz

Home/Pharma News | Posted 30/01/2024

Farmanguinhos/Fiocruz, the Institute of Drug Technology in Brazil, has signed a technology transfer agreement with Pfizer Brazil for the manufacturing of tofacitinib citrate, a generic counterpart to Xeljanz.

Biocon to commercialize biosimilars in 31 European countries

Home/Pharma News | Posted 23/01/2024

Biocon Biologics has successfully integrated Viatris’ biosimilars business in 31 European countries, it was announced in late November 2023.

J&J lawsuits settled over ustekinumab biosimilars

Home/Pharma News | Posted 24/07/2023

Johnson & Johnson (J&J), the maker of Stelara (ustekinumab), settled two lawsuits, one against Amgen, and the other against Alvotech and Teva Pharmaceuticals. Both lawsuits were over proposed ustekinumab biosimilars for the treatment of autoimmune conditions. These were settled in May and June 2023, respectively.

Genfar: Eurofarma's new generic brand in Latin America

Home/Pharma News | Posted 12/12/2023

Eurofarma announced on 29 September 2023 that it completed the acquisition of Laboratorios Genfar. Genfar is a generic drug company owned by the French company Sanofi, with offices in Colombia, Ecuador, and Peru.

Phase III trial results of CinnaGen’s ocrelizumab similar biotherapeutic product

Home/Pharma News | Posted 28/11/2023

Ocrelizumab is a therapeutic monoclonal antibody (mAb) that represents a different scientific approach to treating multiple sclerosis (MS). It is a humanized anti-CD20 mAb that targets CD20 marker on B lymphocytes, a typo of immune cell that plays a key role in the disease and serves as an immunosuppressive drug. Ocrelizumab binds selectively to CD20, which is expressed on the membrane of B cells. When ocrelizumab binds to CD20 on B cells, these cells are eliminated by antibody-dependent cell-mediated cytotoxicity and, to a lesser extent, complement-dependent cytotoxicity.